Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data

@article{Parsons1999MemantineIA,
  title={Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data},
  author={Chris G. Parsons and Wojciech Danysz and G{\"u}nter Quack},
  journal={Neuropharmacology},
  year={1999},
  volume={38},
  pages={735-767}
}

Figures and Tables from this paper

Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?

There are numerous randomized, double-blind, placebo-controlled clinical trials showing that add-on treatment with memantine improves negative and cognitive symptoms, particularly the negative symptoms of schizophrenia, indicating that memantine as adjunctive therapy in schizophrenia helps to ameliorate negative symptoms and cognitive deficits.

Memantine in the treatment of Alzheimer’s disease

Clinical trials have shown that memantine is generally safe and well tolerated, and have provided evidence for its efficacy as assessed by cognitive, behavioral, functional and global measures.

Clinically Tolerated Strategies for NMDA Receptor Antagonism

This chapter reviews the logical process that was applied over the last decade to develop memantine as the first clinically tolerated yet effective agent against NMDAR-mediated neurotoxicity.

NMDA Receptor Antagonists: Repositioning of Memantine as Multitargeting Agent for Alzheimer's Therapy.

The repositioning of memantine as a potential novel therapeutic multitargeting agent for AD is highlighted and the role of NMDA receptors antagonists as potential therapeutic agents to reduce AD is represented.

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

It is suggested that glutamate receptors of the N‐methyl‐D‐aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner in Alzheimer's disease, and memantine would be expected to improve both symptoms (cognition) and to slow down disease progression because it takes over the physiological function of magnesium.

The chemical biology of clinically tolerated NMDA receptor antagonists

Most neuroprotective drugs have failed in clinical trials because of side‐effects, causing normal brain function to become compromised. A case in point concerns antagonists of the

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.

Channel-level factors may allow memantine to block channel activity induced by low, tonic levels of glutamate--an action that might contribute to symptomatic improvement and could theoretically protect against weak excitotoxicity--while sparing synaptic responses required for normal behavioral functioning, cognition and memory.

NMDA receptors in clinical neurology: excitatory times ahead

The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action

...

References

SHOWING 1-10 OF 393 REFERENCES

N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.

The clinical use of NMDA antagonists may prove useful in Parkinson's disease to treat symptoms and retard disease progression and there is evidence that the beneficial effects of anticholinergic drugs and amantadine may be mediated by NMDA receptor blockade.

N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.

The clinical use of NMDA antagonists may prove useful in Parkinson's disease to treat symptoms and retard disease progression and there is evidence that the beneficial effects of anticholinergic drugs and amantadine may be mediated by NMDA receptor blockade.

Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia.

Evidence is presented indicating that this class of compound is neuroprotective in preclinical models of subchronic glutamate toxicity without producing side effects characteristic for other classes of NMDA receptor antagonist.

Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.

Neuroprotection targeting glutamate receptors does apparently not have to be associated with prominent psychotogenicity, and the development and evaluation of new neuroprotective drugs will have to performed in consideration both of the relative safety and of the good clinical effect of the already known and established aminoadamantanes.

Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease

In the present study, 14 parkinsonian patients with motor fluctuations taking L-dopa, were given a supplement of memantine 30 mg/day and in 5 patients, the main parkinsonia features improved significantly and could form a basis for novel therapeutic strategies directed to neutralize the effects of glutamate at striatal and subthalamic levels.

Clinical experience with excitatory amino acid antagonist drugs.

Antagonists of the N-methyl-D-aspartate (NMDA) receptor are furthest advanced in clinical development for stroke, and a similar pattern of side effects is apparent with the majority of agents, however, cardiovascular effects may ultimately define therapeutic index for each drug.

Glutamate in CNS disorders as a target for drug development: an update.

The authors provide an extensive review of new data related to the role of glutamate in CNS disorders, describing new aspects in glutamate and glutamatergic receptors-NMDA receptors, NR2B-selective

Delayed administration of memantine prevents N‐methyl‐D‐aspartate receptor‐mediated neurotoxicity

It is found that 12 μM memantine prevented the death of neonatal rat retinal ganglion cells in primary culture when administered up to 4 hours after the initiation of N‐methyl‐D‐aspartate receptor‐mediated neurotoxicity.

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies

...